Montse Cespedes-Sanchez

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 42 publications

Tolerance and Resistance to Targeted Therapy in NSCLC: Emerging Concepts and Strategies.

Tolerance and Resistance to Targeted Therapy in NSCLC: Emerging Concepts and Strategies.

Journal: JTO clinical and research reports
Published: September 09, 2025

SMARCB1 Deficiency in Tumors Confers a Vulnerability to H3K27 Demethylase Inhibitors via Autophagy Disruption.

SMARCB1 Deficiency in Tumors Confers a Vulnerability to H3K27 Demethylase Inhibitors via Autophagy Disruption.

Journal: Cancer research
Published: August 31, 2025

Landscape and functional impact of variants of unknown significance of immune response genes in human cancer.

Landscape and functional impact of variants of unknown significance of immune response genes in human cancer.

Journal: Cancer gene therapy
Published: July 28, 2025

Advances in Lung Cancer Basic and Translational Research in 2025 - Overview and Perspectives Focusing on NSCLC.

Advances in Lung Cancer Basic and Translational Research in 2025 - Overview and Perspectives Focusing on NSCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: April 24, 2025

DSTYK Inhibition Sensitizes NSCLC to Taxane-Based Chemotherapy.

DSTYK Inhibition Sensitizes NSCLC to Taxane-Based Chemotherapy.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: May 03, 2024

HLA-I levels correlate with survival outcomes in response to immune checkpoint inhibitors in non-small cell lung cancer.

HLA-I levels correlate with survival outcomes in response to immune checkpoint inhibitors in non-small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: October 03, 2023

Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C.

Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C.

Journal: Frontiers in oncology
Published: June 12, 2023

MYC activation impairs cell-intrinsic IFNγ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer.

MYC activation impairs cell-intrinsic IFNγ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer.

Journal: Cell reports. Medicine
Published: June 01, 2022

Biological and clinical perspectives of the actionable gene fusions and amplifications involving tyrosine kinase receptors in lung cancer.

Biological and clinical perspectives of the actionable gene fusions and amplifications involving tyrosine kinase receptors in lung cancer.

Journal: Cancer treatment reviews
Published: March 21, 2022

Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies.

Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies.

Journal: Frontiers in oncology
Published: October 11, 2021

MAX mutant small-cell lung cancers exhibit impaired activities of MGA-dependent noncanonical polycomb repressive complex.

MAX mutant small-cell lung cancers exhibit impaired activities of MGA-dependent noncanonical polycomb repressive complex.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: July 08, 2021

Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma.

Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma.

Journal: British journal of cancer
Published: April 18, 2021
Showing 1-12 of 42

Last Updated: 09/26/2026